Pascal Brière – President, Biogaran, France
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Address: 15 bd Charles de Gaulle 92707 Colombes ,France
Tel: +33 (0)1 55 72 41 00
Biogaran, is an independent French laboratory focused on generic drugs and was born in 1996 at the initiative of the first independent French pharmaceutical group: Servier.
Today the group is second on the French market and produces 55% of its products within the country. The laboratory Biogaran has commissioned the Social Security savings of around € 1 billion since its inception in 1996.
The group distributes a wide variety of pharmaceutical medications through French pharmacies
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France. We…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong…
Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy. The product offering remains…
See our Cookie Privacy Policy Here
